What is the Foreign Direct Investment (FDI) limit permitted by government in Banking-public Sector?

What is the Foreign Direct Investment (FDI) limit permitted by government in Banking-public Sector? Correct Answer 20%

The correct answer is 20%

  • The government has permitted 20% of Foreign Direct Investment in Banking-public Sector.
  • Foreign investment involves investments of funds abroad in exchange for financial return. Foreign investment can be of two types: direct and portfolio investments.
  • A Foreign Direct Investment takes place when a company directly invests in properties such as plant and machinery in foreign countries with a view to undertaking production and marketing of goods and services in those countries.
  • A Foreign Portfolio Investment, on the other hand, is an investment that a company makes into another company by the way of acquiring shares or providing loans to the latter and earns income by way of dividends or interest on loans.
Sectors FDI Limit
Asset reconstruction Companies 100%
Banking-private Sector 74%
Banking-public Sector 20%
Insurance 49%
Pension Sector 49%
White Label ATM operations 100%

Related Questions

Both foreign direct investment (FDI) and foreign portfolio investment (FPI) are related to investment in a country. Which of the following is incorrect regarding FDI and FPI?
In the question below, are given a statement followed by three courses of actions numbered I, II and III. On the basis of the information given, you have to assume everything in the statement to be true, and then decide which of the suggested courses of action logically follow(s) for pursuing. Statement: India’s pharmaceutical sector is now popping out from a shell and making a remarkable recovery. Actually, it has been facing several regulatory challenges in the forms of a recast of foreign direct investment (FDI) policy, pricing policy in the US generics market, patent protection, regulatory approvals and compulsory licensing. Also limited new product launches in the generics space, GST introduction and higher costs associated with regulatory compliance have hurt the sector. Courses of action: I. The government has been engrossed more in policy making and taking resilient decisions for the concerns of the pharma industry. Recently, the government proposed to introduce a new price index for pharmaceutical products, which would serve as a benchmark for determining prices of all medicines sold in the country. II. Meanwhile, pharma companies’ constant investments in R&D have enabled them to develop a basket of robust products for markets across the world. In international markets, pricing pressure on generics sold in the US has eased and this is likely to support the sector. III. Domestic pharma sales grew to Rs. 10,583 crore in May 2018 from Rs. 9,549 crore in the same month last year. The recent clearance by the US Food and Drug Administration to Sun Pharma’s manufacturing plant at Halol in Gujarat brings to an end a two-year import ban it had imposed on the company over quality issues. This is likely to increase sales for the company.